Watchman

What Watchman does

WATCHMAN is a medical device brand that develops, manufactures, and markets permanent left atrial appendage closure (LAAC) implants intended to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF). The implant, approximately the size of a quarter, is delivered via a minimally invasive procedure that seals off the left atrial appendage, the anatomical site where more than 90% of stroke-causing blood clots originate in AFib patients. WATCHMAN operates as a product line within Boston Scientific Corporation's Interventional Cardiology portfolio rather than as a standalone legal entity; Boston Scientific is a publicly traded medical technology company (NYSE: BSX) headquartered in Marlborough, Massachusetts, which acquired the WATCHMAN technology through its 2013 acquisition of Atritech.

The core product family consists of the original WATCHMAN Implant plus the next-generation WATCHMAN FLX and WATCHMAN FLX Pro devices, with the PINNACLE FLX clinical trial demonstrating a 99% implant success rate, a 0.5% major adverse event rate, and 96.2% of patients discontinuing oral anticoagulants at 45 days post-procedure. Clinical and real-world experience spans over 20 years and 10+ studies. Adjacent patient-facing services include an online eligibility questionnaire, an implant-center directory, a patient ambassador peer-support program, and a library of educational content covering AFib, stroke risk, and treatment options. The brand operates region-specific websites in the United States, the United Kingdom, and Germany, and markets the device across the US, UK, Germany, Spain, Italy, and Poland (with France listed as a geographic restriction).

Revenue is generated primarily through hardware sales of the implant device to hospitals and medical centers performing the LAAC procedure, distributed via Boston Scientific's direct field-sales force targeting cardiologists, electrophysiologists, and implanting centers. Pricing is not publicly disclosed; the procedure is reimbursed through Medicare and broad private insurance in the US and through national healthcare systems abroad. The go-to-market combines enterprise sales with a growing direct-to-consumer funnel via the eligibility quiz, ambassador testimonials, and physician discussion guides designed to drive patient-initiated referrals. WATCHMAN does not have a separate management team, subsidiaries, or independent funding profile disclosed in the input, and is operationally embedded in its parent's commercial and clinical infrastructure.

Name

Watchman

Legal name

Boston Scientific Corporation

Website

https://watchman.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

WATCHMAN is a medical device brand offering permanent left atrial appendage closure implants that reduce stroke risk in patients with non-valvular atrial fibrillation. It operates as a product line within Boston Scientific's Interventional Cardiology portfolio and has treated 600,000+ patients globally over 20+ years.

Ownership category

akta.pro rank

Product category

Cardiac Medical Devices / Left Atrial Appendage Closure Implants

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

akta.pro primary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

akta.pro secondary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Left atrial appendage closure
• Stroke prevention implant
• Atrial fibrillation device
• Cardiac medical device
• LAAC implant

Headquarters

HQ city

Jupiter

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Technology or R&D, Personnel

Revenue model

1. Medical Device Sales: Revenue generated from the sale of WATCHMAN Implant devices to hospitals and medical centers that perform the left atrial appendage closure procedure. The device is a one-time implant, but procedures typically include associated equipment, follow-up care, and physician services.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

WATCHMAN is a permanent, minimally invasive left atrial appendage closure (LAAC) implant designed to reduce stroke risk in patients with non-valvular atrial fibrillation by sealing off the LAA where stroke-causing blood clots commonly form. The product line includes the original WATCHMAN Implant and the next-generation WATCHMAN FLX Pro device, sold to hospitals and medical centers through Boston Scientific's direct sales force.

Product overview

Watchman is a medical device company (subsidiary of Boston Scientific) offering the WATCHMAN Implant family - a line of permanent, minimally invasive left atrial appendage closure (LAAC) devices designed to reduce stroke risk in patients with non-valvular atrial fibrillation. The core product portfolio includes the original WATCHMAN Implant and the next-generation WATCHMAN FLX Pro. The company supports its devices with patient-facing services including an eligibility quiz, a directory of implant centers, an ambassador peer-support program, and comprehensive educational resources including brochures, discussion guides, and articles covering AFib understanding, treatment options, and post-procedure care.

Differentiator

Problem solved

Functional benefit

Brands

• WATCHMAN FLX: Left atrial appendage closure implant device for stroke risk reduction in non-valvular AFib patients
• WATCHMAN FLX Pro

Products and services

• WATCHMAN Implant A permanent, minimally invasive left atrial appendage closure (LAAC) implant designed to reduce stroke risk in patients with non-valvular atrial fibrillation by sealing off the LAA where blood clots commonly form. Sold to hospitals and medical centers performing the implant procedure.
• WATCHMAN FLX Pro Next-generation LAAC device featuring improved design for enhanced placement and sealing in the left atrial appendage. Built on the WATCHMAN FLX platform that demonstrated 99% implant success rate and 0.5% major adverse event rate.

Quantifiable outcome

• 96% of patients able to stop blood thinners 45 days after the WATCHMAN Implant procedure
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Boston Scientific CorporationcoreOEM/ Whitelabel/ Licensing PartnerBoston Scientific is the parent company and manufacturer of the WATCHMAN Implant. WATCHMAN operates as a product line within Boston Scientific's Interventional Cardiology portfolio. Boston Scientific is a global medical device company headquartered in Marlborough, Massachusetts.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Occlutech: Occlutech develops left atrial appendage occlusion devices sold primarily in Europe, offering a competing transcatheter LAAC solution to WATCHMAN in select international markets where both are CE-marked.
• Conformal Medical: Conformal Medical is developing a next-generation LAAC device targeting the same NVAF patients as WATCHMAN, positioning it as a focused emerging competitor in the transcatheter left atrial appendage closure category.
• CardioMech: CardioMech is developing transcatheter structural heart devices serving the same interventional cardiology accounts and procedure workflows where WATCHMAN is implanted, with adjacent but overlapping clinical applications.
• SentreHEART: SentreHEART's LARIAT system delivers suture-based epicardial LAA closure, providing an alternative modality for the same stroke-risk AFib population and creating partial overlap with WATCHMAN's clinical value proposition.
• JenaValve Technology: JenaValve is a transcatheter heart valve developer operating in the structural heart category that intersects with WATCHMAN's customer base of structural heart interventionalists and cardiac surgeons.

Broad incumbents

• Medtronic: Medtronic is a large incumbent cardiac device manufacturer with structural heart, AFib ablation, and rhythm management portfolios that overlap with WATCHMAN's electrophysiology customer base even where Medtronic lacks a direct LAAC device.
• Edwards Lifesciences: Edwards is the structural heart category leader (TAVR, TMVR) selling into the same cardiology accounts and interventional cardiology service lines that implant WATCHMAN, making it a broad incumbent reference point for LAAC economics.

Regional players

• LifeTech Scientific: LifeTech Scientific (Shenzhen) manufactures LAAC and other interventional cardiac devices primarily for China and Asia-Pacific, making it a regional peer competing in adjacent geographies to WATCHMAN.

Direct peers

• Abbott: Abbott's Amplatzer Amulet is the primary head-to-head transcatheter left atrial appendage closure device competing with WATCHMAN in the same NVAF patient population, sold through overlapping electrophysiology and cardiology channels.
• AtriCure: AtriCure's AtriClip is a surgical left atrial appendage exclusion device that addresses the same NVAF stroke-risk population as WATCHMAN via a different (epicardial) delivery, making it a directly comparable LAA closure competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/WATCHMANBostonSci

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Watchman